D-8147 Duvelisib, Free Base, >99%

Synonyms : [IPI-145] [INK-1197]

Related Terms : [Copiktra]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 49
  • 44
  • 37
  • 5,300
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 75
  • 67
  • 56
  • 8,200
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 119
  • 107
  • 90
  • 12,900
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 162
  • 146
  • 122
  • 17,600
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 218
  • 196
  • 165
  • 23,700
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 359
  • 323
  • 272
  • 39,000
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 722
  • 651
  • 547
  • 78,500
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 416.86
  • C22H17ClN6O
  • [1201438-56-3]

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Duvelisib, also known as IPI-145, is a potent inhibitor of phosphoinositide-3-kinase (PI3K) [delta] and PI3K [gamma]. It inhibits PI3K [delta] and [gamma] with Ki values of 23 and 243 pM, cell-free IC50 values of 2.5 and 27.4 nM, and cellular IC50 values of 1 nM and 43 nM, respectively. It was active in preclinical models of arthritis. Porter J.R., et al. "The potent phosphoinositide-3-kinase-(delta, gamma) inhibitor IPI-145 is active in preclinical models of arthritis and well tolerated in healthy adult subjects." http://infi.com/pdfs/ACR_ARHP2012.pdf
  • Duvelisib was active and well-tolerated in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas. Horwitz S., et al. "Preliminary Safety and Efficacy of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ, γ in Patients with Relapsed/Refractory T-Cell Lymphoma." http://infi.com/pdfs/LuganoTcell.pdf
  • A phase I trial demonstrated that duvelisib was well tolerated and showed initial clinical activity in patients with indolent non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. Flinn I.W., et al. "Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies." Blood (ASH Annual Meeting Abstracts) 120: Abstract 3663 (2012).
  • Other CAS numbers previously assigned to IPI-145 free base, namely 1355213-59-0 and 1428465-12-6, have been deleted by CAS and are no longer in use.
  • Duvelisib is the active ingredient in the drug product sold under the trade name Copiktra®.  This drug is currently approved in at least one country for the treatnent of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies  NOTE: THE DUVELISIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT COPIKTRA®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.